Advanced

Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network

Dreyling, Martin; Amador, Virginia; Callanan, Mary; Jerkeman, Mats LU ; Le Goui, Steven; Pott, Christiane; Rule, Simon and Zaja, Francesco (2015) In Leukemia & Lymphoma 56(4). p.866-876
Abstract
Mantle cell lymphoma (MCL) is a distinct subtype of malignant lymphoma which is characterized by the chromosomal translocation t(11;14)(q13;q32) resulting in constitutional overexpression of cyclin D1 and cell cycle dysregulation in almost all cases. Clinically, MCL shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3-5 years. However, recently a subset of 15% long-term survivors has been identified with a rather indolent clinical course. Targeted strategies include the proteasome inhibitors, immune modulatory drugs (IMiDs), mammalian target of rapamycin (mTOR) inhibitors and especially inhibitors of the B-cell receptor pathway. Our recent annual conference focused on the molecular... (More)
Mantle cell lymphoma (MCL) is a distinct subtype of malignant lymphoma which is characterized by the chromosomal translocation t(11;14)(q13;q32) resulting in constitutional overexpression of cyclin D1 and cell cycle dysregulation in almost all cases. Clinically, MCL shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3-5 years. However, recently a subset of 15% long-term survivors has been identified with a rather indolent clinical course. Targeted strategies include the proteasome inhibitors, immune modulatory drugs (IMiDs), mammalian target of rapamycin (mTOR) inhibitors and especially inhibitors of the B-cell receptor pathway. Our recent annual conference focused on the molecular pathogenesis of the disease and how these underlying molecular alterations may guide the selection and integration of innovative approaches for therapy. This review of the meeting covers in particular the identification of indolent cases, and deals with the role of the B-cell receptor pathway in MCL, as well as the detection of minimal residual disease and implementation of molecular approaches in current clinical trials. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Mantle cell lymphoma, chemotherapy, targeted therapy, molecular, pathogenesis, minimal residual disease
in
Leukemia & Lymphoma
volume
56
issue
4
pages
866 - 876
publisher
Taylor & Francis
external identifiers
  • wos:000353612700009
  • scopus:84929085168
ISSN
1042-8194
DOI
10.3109/10428194.2014.940584
language
English
LU publication?
yes
id
d067018c-11f3-43d6-89e7-4eac4a7b5079 (old id 7439153)
date added to LUP
2015-07-03 07:09:32
date last changed
2017-08-06 03:58:17
@article{d067018c-11f3-43d6-89e7-4eac4a7b5079,
  abstract     = {Mantle cell lymphoma (MCL) is a distinct subtype of malignant lymphoma which is characterized by the chromosomal translocation t(11;14)(q13;q32) resulting in constitutional overexpression of cyclin D1 and cell cycle dysregulation in almost all cases. Clinically, MCL shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3-5 years. However, recently a subset of 15% long-term survivors has been identified with a rather indolent clinical course. Targeted strategies include the proteasome inhibitors, immune modulatory drugs (IMiDs), mammalian target of rapamycin (mTOR) inhibitors and especially inhibitors of the B-cell receptor pathway. Our recent annual conference focused on the molecular pathogenesis of the disease and how these underlying molecular alterations may guide the selection and integration of innovative approaches for therapy. This review of the meeting covers in particular the identification of indolent cases, and deals with the role of the B-cell receptor pathway in MCL, as well as the detection of minimal residual disease and implementation of molecular approaches in current clinical trials.},
  author       = {Dreyling, Martin and Amador, Virginia and Callanan, Mary and Jerkeman, Mats and Le Goui, Steven and Pott, Christiane and Rule, Simon and Zaja, Francesco},
  issn         = {1042-8194},
  keyword      = {Mantle cell lymphoma,chemotherapy,targeted therapy,molecular,pathogenesis,minimal residual disease},
  language     = {eng},
  number       = {4},
  pages        = {866--876},
  publisher    = {Taylor & Francis},
  series       = {Leukemia & Lymphoma},
  title        = {Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network},
  url          = {http://dx.doi.org/10.3109/10428194.2014.940584},
  volume       = {56},
  year         = {2015},
}